DarioHealth recently saw its consensus analyst price target lowered from $19.75 to $18.25. This adjustment reflects a cautious reassessment of the company’s growth trajectory. Market watchers are weighing both positives, such as a promising new product pipeline, alongside persistent concerns over recent revenue trends. Stay tuned to discover how investors can track these shifts and remain informed about the evolving DarioHealth story.
Stay updated as the Fair Value for DarioHealth shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on DarioHealth.
Analyst sentiment toward DarioHealth remains mixed, with recent commentary reflecting both optimism about the company’s potential and caution regarding ongoing challenges. Below are the key takeaways from recent analyst research:
🐂 Bullish Takeaways
-
TD Cowen substantially increased its price target for DarioHealth to $11 from just 60c after reviewing Q3 results. This marks a notable upward revision and signals confidence in the company’s longer-term prospects.
-
The analyst at TD Cowen cited a strong product pipeline as a primary driver of potential recovery and highlighted the expectation of meaningful improvement by 2026.
🐻 Bearish Takeaways
-
Despite the price target increase, TD Cowen maintained a Hold rating on the stock and emphasized ongoing revenue weakness that persisted through the recent quarter.
-
The Hold stance signals lingering concerns over near-term execution and the uncertainty surrounding the company’s ability to return to consistent top-line growth.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!
-
DarioHealth’s Board of Directors has initiated a comprehensive strategic review to explore options for maximizing shareholder value. These options may include a sale, merger, or a continuation of its current standalone strategy.
-
The company successfully completed a $17.5 million private placement with 10 investors, which significantly strengthened its financial position.
-
Six new employer clients have adopted DarioHealth’s value-based pricing model. This expansion increases access to its integrated digital health solutions for chronic conditions.
-
DarioHealth released updated earnings guidance and is projecting strong revenue acceleration anticipated for 2026.
-
Consensus Analyst Price Target has fallen from $19.75 to $18.25.
-
Discount Rate has risen slightly from 9.19% to 9.21%.
-
Revenue Growth estimate remains essentially unchanged at approximately 11.4%.
-
Net Profit Margin forecast is stable at roughly 7.1%.
-
Future P/E multiple has fallen from 84.6x to 78.3x.